Affilogic is a private biotech company specialized in discovering and developing affinity proteins, Nanofitins®, through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

Each Nanofitin® is 20 times smaller than an antibody and hyperstable. Nanofitins® are easily combined by simple, rapid, and proven methods to design an ideal targeted molecule.

Affilogic is investing internally in 4 programs that leverage the core advantages of Nanofitins®:

1 – Bus2Brain: Enhanced brain uptake of biologics to reignite CNS therapies
2 – Respitude: Inhaled antiviral Nanofitin® therapeutics against respiratory infections
3 – GI Job: Targeting GI tract diseases by oral administration
4 – ODC: Small-size Nanofitin®-drug conjugates against solid tumors with a new therapeutic window

Moreover, with NanoVector, Affilogic is partnering with third parties to deliver their therapeutic compounds to specific cells/organs (ASO, siRNA, nanoparticles, antibodies, enzymes, peptides, CAR-T, AAV…).

Such programs illustrate the versatility of Nanofitins®, designed as APIs or as vectors for the specific transport of therapeutic molecules, administered systemically, via the oral route for a local effect in the GI tract, or via direct pulmonary delivery.